Labetalol and soluble endoglin aggravate bile acid retention in mice with ethinylestradiol-induced cholestasis
Labetalol is used for the therapy of hypertension in preeclampsia. Preeclampsia is characterized by high soluble endoglin (sEng) concentration in plasma and coincides with intrahepatic cholestasis during pregnancy (ICP), which threatens the fetus with the toxicity of cumulating bile acids (BA). Ther...
Saved in:
Main Authors: | Ivone Cristina Igreja Sá (Author), Katarina Tripska (Author), Fatemeh Alaei Faradonbeh (Author), Milos Hroch (Author), Hana Lastuvkova (Author), Jolana Schreiberova (Author), Marian Kacerovsky (Author), Miguel Pericacho (Author), Petr Nachtigal (Author), Stanislav Micuda (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2023-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Endoglin aggravates peritoneal fibrosis by regulating the activation of TGF-β/ALK/Smads signaling
by: Qian Huang, et al.
Published: (2022) -
Mitigation of intrahepatic cholestasis induced by 17α-ethinylestradiol via nanoformulation of Silybum marianum L.
by: Maha B. Salem, et al.
Published: (2024) -
Paeoniflorin alleviates 17α-ethinylestradiol-induced cholestasis via the farnesoid X receptor-mediated bile acid homeostasis signaling pathway in rats
by: Rulin Wang, et al.
Published: (2022) -
Attenuation of cardiovascular responses to tracheal extubation with labetalol
by: Mokhtar M Younes, et al.
Published: (2017) -
Baicalin Protects Against 17α-Ethinylestradiol-Induced Cholestasis via the Sirtuin 1/Hepatic Nuclear Receptor-1α/Farnesoid X Receptor Pathway
by: Jinyu Yang, et al.
Published: (2020)